Tony Berberabe, MPH

Active Surveillance Protocols Needed for Prostate Cancer

May 16th 2015

As the AS strategy gains a foothold among urologists both here in the US and around the world, a study presented at the 110th Annual Scientific Meeting of the American Urological Association suggests that among men in the US, very few are following the stringent protocol for AS that is recommended by major academic institutions.

Presence of AR-V7 in Stromal, Epithelial Tissue Suggests Role in Carcinogenesis

May 16th 2015

The role of androgen receptor variant-7 in patients with early stage prostate cancer is not well characterized but data presented at the 2015 American Urological Association (AUA) Meeting is bringing the discussion into focus.

Olaparib Nears 90% Response in Molecular Subgroup of mCRPC

April 21st 2015

Treatment with olaparib demonstrated a durable overall response rate of 87.5% in a biomarker-defined subgroup of men with pretreated sporadic metastatic castration-resistant prostate cancer in a phase II multi-step adaptive trial.

Tasquinimod Development in mCRPC Halted After Phase III Study Falls Short

April 16th 2015

Topline results announced today from the phase III Swedish trial 10TASQ10 demonstrated that tasquinimod failed to extend overall survival in men with metastatic castrate-resistant prostate cancer.

STRIVE Data Further Demonstrate PFS Benefit With Enzalutamide Over Bicalutamide

April 2nd 2015

Treatment with enzalutamide reduced the risk of progression by 76% compared with bicalutamide in men with castration-resistant prostate cancer.

Advanced Bladder Cancer Increases Suicide Risk, Study Says

March 27th 2015

Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.

PREVAIL, TERRAIN Updates Show Improved OS With Enzalutamide

March 24th 2015

Two studies investigating enzalutamide in men with early stage metastatic castration-resistant prostate cancer further confirmed the overall survival and progression-free survival benefit of the agent over placebo.

Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise

March 16th 2015

With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.

Task Force PSA Recommendation Needs Updating, LUGPA President Says

March 16th 2015

A United States Preventive Services Task Force recommendation against the use of prostate specific antigen testing needs to be updated, said Gary Kirsh, MD, president of the Large Urology Group Practice Association.

Making Sense of the Prostate Cancer Screening Debate

March 14th 2015

Leonard G. Gomella, MD, told attendees at the 8th Annual IPCC that the decision to screen or not to screen for prostate cancer boiled down to "using common sense, shared decision making, and choosing the right patients to screen."

PD-1 Agents Vie for Frontline Spot in Melanoma Immunotherapy

February 27th 2015

New checkpoint blockade agents that target the PD-1 pathway are moving forward quickly in the melanoma treatment paradigm and likely will become a frontline immunotherapy choice for patients with advanced or metastatic disease, according to Jason J. Luke, MD, FACP, a leading researcher in the field.

Chemotherapy for CLL Not Yet Obsolete But in Flux as New Agents Gain Ground

February 21st 2015

Standard chemotherapy remains part of the treatment paradigm for patients with chronic lymphocytic leukemia but its role is undergoing a major shift as significant advances are being made in novel therapies.

ASCO Supports ACS Guidelines for Prostate Cancer Survivor Care

February 15th 2015

ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer specialists and primary care physicians deliver high quality of care to patients with localized disease.

Oral Chemotherapy Use Benefits From Safety Self-Assessments

February 9th 2015

The Institute for Safe Medication Practices (ISMP) and the Institute for Safe Medication Practices Canada (ISMP Canada) worked collaboratively to create a self-assessment tool to assist oncologists in evaluating safe practices related to medication use.

Clinical and Economic Impact of Gene Expression Testing in Localized Prostate Cancer

February 4th 2015

Biopsy-based cell cycle progression gene expression testing can aid in the stratification of patients with localized prostate cancer based on disease aggressiveness.

Who Will Join the 2015 Class of the Giants of Cancer Care?

January 24th 2015

CancerLinQ To Be Rolled Out to 15 Community Practices, Large Cancer Centers

January 21st 2015

The first iteration of the American Society of Clinical Oncology's (ASCO's) endeavor to capture and harness big data, CancerLinQ, is scheduled for release in late 2015.

When the Patient Can't Afford His Cancer Treatment

January 8th 2015

One of the leading non-clinical attributes that affect how oncologists decide which therapeutic agent to prescribe over another is patient affordability.

The Evolving Treatment Landscape in Advanced Melanoma

December 18th 2014

Metastatic melanoma is associated with a poor prognosis, but recent breakthroughs in tumor biology and immune regulation have led to the development of agents that could change clinical practice.

Innovative Payment Models in Cancer Care

December 15th 2014

Faced with steep regulations, slashed reimbursement rates, and a shift in focus from fee-for-service (FFS) to delivering value, insurers and physician groups are experimenting with new forms of payment incentives.